Published in Ann Neurol on December 01, 2008
Recent advances in lentiviral vector development and applications. Mol Ther (2010) 1.89
Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther (2009) 1.52
Spatiotemporally separable Shh domains in the midbrain define distinct dopaminergic progenitor pools. Proc Natl Acad Sci U S A (2009) 1.37
Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology (2011) 1.21
Neuromechanical principles underlying movement modularity and their implications for rehabilitation. Neuron (2015) 1.09
Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients. J Neurol (2009) 1.05
Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc Natl Acad Sci U S A (2010) 1.05
The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies. Neurobiol Dis (2009) 0.92
Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs (2010) 0.89
A dual-hit animal model for age-related parkinsonism. Prog Neurobiol (2009) 0.85
Pluripotent stem cells for Parkinson's disease: progress and challenges. Stem Cell Res Ther (2013) 0.80
Molecular heterogeneity of midbrain dopaminergic neurons - Moving toward single cell resolution. FEBS Lett (2015) 0.78
Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model. Nano Lett (2017) 0.76
Transplantation of Airway Epithelial Stem/Progenitor Cells: A Future for Cell-Based Therapy. Am J Respir Cell Mol Biol (2017) 0.75
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell (1996) 9.03
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med (2003) 8.59
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature (2002) 6.51
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol (2000) 6.21
Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet (1994) 5.49
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab (2003) 5.27
Neurogenesis in adult subventricular zone. J Neurosci (2002) 5.22
Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci (2006) 4.98
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med (2003) 4.51
Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A (2002) 4.20
Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron (2000) 4.18
Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience (1991) 4.05
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science (2000) 3.89
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med (1995) 3.64
Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain (2005) 3.61
Neural induction, the default model and embryonic stem cells. Nat Rev Neurosci (2002) 3.53
Responses of monkey dopamine neurons during learning of behavioral reactions. J Neurophysiol (1992) 3.46
Direct neural fate specification from embryonic stem cells: a primitive mammalian neural stem cell stage acquired through a default mechanism. Neuron (2001) 3.42
Identification of intrinsic determinants of midbrain dopamine neurons. Cell (2006) 3.31
Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci (1999) 3.06
AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet (2003) 2.81
Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med (2008) 2.80
Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci U S A (1998) 2.76
In vivo growth factor expansion of endogenous subependymal neural precursor cell populations in the adult mouse brain. J Neurosci (1996) 2.72
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology (2003) 2.65
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg (2005) 2.53
Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg (2002) 2.45
Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science (1997) 2.40
Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. Stem Cells (2006) 2.37
Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes (2002) 2.36
Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet (2005) 2.28
Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis (2006) 2.23
Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J Biol Chem (1992) 2.21
Dendrodendritic inhibition through reversal of dopamine transport. Science (2001) 2.08
Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. Science (1992) 2.02
Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science (1994) 1.98
Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature (1996) 1.83
Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol (1999) 1.75
Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur J Neurosci (2002) 1.75
Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci (2000) 1.74
In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci U S A (2000) 1.67
Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci (2005) 1.67
Adult neurogenesis in mammals: an identity crisis. J Neurosci (2002) 1.61
Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci (1996) 1.61
Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci (1998) 1.59
The ciliary neurotrophic factor/leukemia inhibitory factor/gp130 receptor complex operates in the maintenance of mammalian forebrain neural stem cells. J Neurosci (2001) 1.59
Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord (1998) 1.55
Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol (1999) 1.55
Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med (2005) 1.49
Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci (2001) 1.48
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol (2006) 1.46
Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res (1990) 1.46
Blastula-stage stem cells can differentiate into dopaminergic and serotonergic neurons after transplantation. Exp Neurol (1998) 1.45
Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Ann Neurol (2003) 1.44
Orphan nuclear receptor Nurr1 directly transactivates the promoter activity of the tyrosine hydroxylase gene in a cell-specific manner. J Neurochem (2003) 1.40
Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol (1998) 1.39
The production and use of cells as therapeutic agents in neurodegenerative diseases. Lancet Neurol (2003) 1.33
Transplanted dopamine neurons derived from primate ES cells preferentially innervate DARPP-32 striatal progenitors within the graft. Eur J Neurosci (2006) 1.32
Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol (2000) 1.30
Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med (1995) 1.30
Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis (2007) 1.26
Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci U S A (1997) 1.26
Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain (2000) 1.24
Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci (2004) 1.23
Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol (1999) 1.22
Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol Dis (2004) 1.22
Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol (1996) 1.21
TrnR2, a novel receptor that mediates neurturin and GDNF signaling through Ret. Neuron (1997) 1.20
Crossroads in GDNF therapy for Parkinson's disease. Mov Disord (2006) 1.19
Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation. Eur J Neurosci (2004) 1.18
Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther (2000) 1.18
Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther (2002) 1.15
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis (2007) 1.15
Pitx3 activates mouse tyrosine hydroxylase promoter via a high-affinity binding site. J Neurochem (2001) 1.15
Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase. Nature (1997) 1.14
Orphan nuclear receptor Nurr1 is essential for Ret expression in midbrain dopamine neurons and in the brain stem. Mol Cell Neurosci (2001) 1.14
Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci U S A (1997) 1.14
Firing properties of substantia nigra dopaminergic neurons in freely moving rats. Life Sci (1985) 1.13
Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci (2000) 1.13
Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci U S A (1990) 1.13
Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol (1995) 1.13
Marmoset monkey models of Parkinson's disease: which model, when and why? Brain Res Bull (2005) 1.13
Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci U S A (1989) 1.11
Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. J Comp Neurol (2007) 1.11
Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci (2002) 1.10
Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur J Neurosci (2003) 1.10
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord (2007) 1.10
Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U S A (1994) 1.09
Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol (1998) 1.08
Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther (2002) 1.08
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol (2002) 3.84
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med (2005) 3.46
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis (2006) 2.23
Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol (2006) 2.17
The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci (2003) 1.92
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90
Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord (2011) 1.87
Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord (2012) 1.76
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Neurosurgery (2002) 1.54
Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. J Comp Neurol (2003) 1.49
Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys. Cereb Cortex (2004) 1.48
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci (2011) 1.45
Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One (2011) 1.40
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord (2010) 1.39
Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol (2004) 1.35
Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol (2002) 1.32
Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res (2010) 1.30
Nurr1 in Parkinson's disease and related disorders. J Comp Neurol (2006) 1.27
Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis (2007) 1.26
Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem (2010) 1.25
Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol (2004) 1.23
Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain (2012) 1.22
Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol (2002) 1.19
Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor α. Cell Rep (2013) 1.19
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis (2007) 1.15
Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther (2009) 1.14
Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. J Comp Neurol (2007) 1.11
Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci (2002) 1.10
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery (2009) 1.10
Proteasome inhibition and Parkinson's disease modeling. Ann Neurol (2006) 1.10
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord (2007) 1.10
Chronic ischemic stroke model in cynomolgus monkeys: behavioral, neuroimaging and anatomical study. Neurol Res (2003) 1.09
Lewy body pathology in fetal grafts. Ann N Y Acad Sci (2010) 1.08
Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp Neurol (2005) 1.06
Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Exp Neurol (2008) 1.03
Gene therapy for Parkinson's disease. Mov Disord (2010) 1.02
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis (2011) 1.02
Trophic factors therapy in Parkinson's disease. Prog Brain Res (2009) 1.02
Animal models of Huntington's disease. ILAR J (2007) 1.01
Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis (2005) 1.01
Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol (2003) 0.99
Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol (2009) 0.98
Testing NF-κB-based therapy in hemiparkinsonian monkeys. J Neuroimmune Pharmacol (2012) 0.98
Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A (2006) 0.96
Doublecortin-expressing cells persist in the associative cerebral cortex and amygdala in aged nonhuman primates. Front Neuroanat (2009) 0.95
GFAP knockout mice have increased levels of GDNF that protect striatal neurons from metabolic and excitotoxic insults. J Comp Neurol (2003) 0.95
Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res (2007) 0.95
Gene therapy for Huntington's disease. Neurobiol Dis (2011) 0.94
Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol (2003) 0.94
Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther (2008) 0.94
Cell transplantation and gene therapy in Parkinson's disease. Mt Sinai J Med (2011) 0.91
Huntington's disease: pathological mechanisms and therapeutic strategies. Cell Transplant (2007) 0.91
Etiology of Parkinson's disease: Genetics and environment revisited. Proc Natl Acad Sci U S A (2002) 0.91
Primate models of Parkinson's disease. Exp Neurol (2003) 0.91
Neuropathology in transplants in Parkinson's disease: implications for disease pathogenesis and the future of cell therapy. Prog Brain Res (2012) 0.89
Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis (2008) 0.89
Survival and early differentiation of human neural stem cells transplanted in a nonhuman primate model of stroke. J Neurosurg (2006) 0.89
β-Secretase-1 elevation in aged monkey and Alzheimer's disease human cerebral cortex occurs around the vasculature in partnership with multisystem axon terminal pathogenesis and β-amyloid accumulation. Eur J Neurosci (2010) 0.89
Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology (2006) 0.88
Modeling Parkinson's disease. Ann Neurol (2009) 0.88
Enduring cortical alterations after a single in-vivo treatment of HIV-1 Tat. Neuroreport (2012) 0.87
Extensive neuroprotection by choroid plexus transplants in excitotoxin lesioned monkeys. Neurobiol Dis (2006) 0.87
Decreased alpha-synuclein expression in the aging mouse substantia nigra. Exp Neurol (2009) 0.87
Excitotoxic and metabolic damage to the rodent striatum: role of the P75 neurotrophin receptor and glial progenitors. J Comp Neurol (2002) 0.86
Cell therapy for Parkinson's disease: what next? Mov Disord (2013) 0.86
Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys. Neurobiol Aging (2008) 0.86
Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant (2006) 0.86
Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease. Neurotox Res (2009) 0.85
α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis (2010) 0.84
Effects of estrogen replacement therapy on cholinergic basal forebrain neurons and cortical cholinergic innervation in young and aged ovariectomized rhesus monkeys. J Comp Neurol (2004) 0.83
Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog Brain Res (2002) 0.83
Distribution of high affinity choline transporter immunoreactivity in the primate central nervous system. J Comp Neurol (2003) 0.83
Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord (2009) 0.83
RET expression does not change with age in the substantia nigra pars compacta of rhesus monkeys. Neurobiol Aging (2005) 0.82
Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci Rep (2013) 0.81
Deep brain stimulation for treatment of obesity in rats. J Neurosurg (2007) 0.81
Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism Relat Disord (2007) 0.81
Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord (2013) 0.81
Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiol Dis (2007) 0.80
Neuropathological study 16 years after autologous adrenal medullary transplantation in a Parkinson's disease patient. Mov Disord (2007) 0.80
Age-related alterations in GABA(A) receptor subunits in the nonhuman primate hippocampus. Brain Res (2006) 0.80
Are growth factors the answer? Parkinsonism Relat Disord (2009) 0.79
GDNF family ligands: a potential future for Parkinson's disease therapy. CNS Neurol Disord Drug Targets (2011) 0.79
Peripheral alpha-synuclein and Parkinson's disease. Mov Disord (2014) 0.78
The prion hypothesis of Parkinson's disease. Curr Neurol Neurosci Rep (2015) 0.78
Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases. Drug Deliv Transl Res (2011) 0.77
Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration. J Pharmacol Exp Ther (2003) 0.77
In vivo evaluation of [(123)I]MNI-420: a novel single photon emission computed tomography radiotracer for imaging of adenosine 2A receptors in brain. Nucl Med Biol (2013) 0.76
The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys. Exp Neurol (2002) 0.76
Introduction: gene therapy has gone from a pipe dream to clinical reality. Neurobiol Dis (2012) 0.76
How strong is the evidence that Parkinson's disease is a prion disorder? Curr Opin Neurol (2016) 0.75
Gene therapy approaches for the treatment of Parkinson's disease. Handb Clin Neurol (2007) 0.75
RNA amplification of bromodeoxyuridine labeled newborn neurons in the monkey hippocampus. J Neurosci Methods (2004) 0.75
DELIVERY OF NEUROTROPHIC FACTORS TO THE CNS USING ENCAPSULATED CELLS: DEVELOPING TREATMENTS FOR NEURODEGENERATIVE DISEASES. Cell Transplant (1995) 0.75